Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Cut to $318.00 by Analysts at Stifel Nicolaus

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price objective lowered by Stifel Nicolaus from $444.00 to $318.00 in a research note issued to investors on Friday,Benzinga reports. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Stifel Nicolaus’ price objective indicates a potential upside of 56.09% from the company’s current price.

ALNY has been the topic of a number of other reports. Weiss Ratings upgraded shares of Alnylam Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, May 4th. Bank of America cut their target price on shares of Alnylam Pharmaceuticals from $460.00 to $410.00 and set a “buy” rating on the stock in a research note on Tuesday, July 14th. Truist Financial reduced their target price on shares of Alnylam Pharmaceuticals from $505.00 to $410.00 and set a “buy” rating on the stock in a report on Monday, July 13th. Wells Fargo & Company lifted their price target on shares of Alnylam Pharmaceuticals from $376.00 to $377.00 and gave the stock an “equal weight” rating in a research note on Friday, May 1st. Finally, Morgan Stanley boosted their price target on shares of Alnylam Pharmaceuticals from $370.00 to $400.00 and gave the stock an “equal weight” rating in a report on Friday, July 10th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $437.22.

Alnylam Pharmaceuticals Trading Down 0.9%

Shares of ALNY stock traded down $1.75 on Friday, hitting $203.73. The stock had a trading volume of 548,368 shares, compared to its average volume of 1,353,112. The company has a debt-to-equity ratio of 0.94, a current ratio of 3.13 and a quick ratio of 3.06. The firm has a market capitalization of $27.20 billion, a P/E ratio of 55.57 and a beta of 0.27. Alnylam Pharmaceuticals has a 1 year low of $197.81 and a 1 year high of $495.55. The company’s 50 day moving average price is $289.80 and its 200-day moving average price is $312.07.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.99 EPS for the quarter, beating analysts’ consensus estimates of $0.87 by $1.12. Alnylam Pharmaceuticals had a return on equity of 85.76% and a net margin of 11.72%.The company had revenue of $1.17 billion during the quarter, compared to analysts’ expectations of $1.12 billion. During the same period last year, the business posted ($0.44) EPS. Alnylam Pharmaceuticals’s revenue for the quarter was up 96.4% on a year-over-year basis. Analysts anticipate that Alnylam Pharmaceuticals will post 7.35 earnings per share for the current year.

Insider Activity

In other news, Director David E. I. Pyott sold 3,830 shares of the company’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $299.18, for a total transaction of $1,145,859.40. Following the completion of the transaction, the director directly owned 1,582 shares of the company’s stock, valued at approximately $473,302.76. This represents a 70.77% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 0.86% of the company’s stock.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the business. MV Capital Management Inc. acquired a new position in Alnylam Pharmaceuticals in the fourth quarter valued at approximately $25,000. Caitong International Asset Management Co. Ltd acquired a new stake in Alnylam Pharmaceuticals during the third quarter worth approximately $29,000. HM Payson & Co. purchased a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter worth approximately $27,000. Golden State Wealth Management LLC lifted its position in shares of Alnylam Pharmaceuticals by 100.0% during the 4th quarter. Golden State Wealth Management LLC now owns 72 shares of the biopharmaceutical company’s stock worth $29,000 after buying an additional 36 shares during the last quarter. Finally, Manchester Capital Management LLC lifted its position in shares of Alnylam Pharmaceuticals by 600.0% during the 4th quarter. Manchester Capital Management LLC now owns 84 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 72 shares during the last quarter. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals News Roundup

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Alnylam reported second-quarter revenue of approximately $1.29 billion, up 66.9% year over year, while adjusted earnings of $1.84 per share exceeded some analyst estimates. The company also highlighted continued strength across its transthyretin (TTR) franchise. Alnylam second-quarter earnings report
• Positive Sentiment: Chardan Capital reaffirmed its “buy” rating and set a $425 price target, while Needham maintained a “buy” rating with a revised $357 target. These targets imply substantial potential upside if Alnylam executes on its pipeline and commercial plans. Analyst rating reports
• Neutral Sentiment: Alnylam’s earnings performance was mixed: quarterly profit improved substantially from the prior year, but reported revenue of about $1.29 billion fell short of the roughly $1.32 billion consensus estimate in several reports. Alnylam second-quarter earnings results
• Negative Sentiment: The primary catalyst for the selloff was Alnylam’s reduction of its fiscal 2026 outlook. Product-revenue guidance was lowered to approximately $5.3 billion-$5.7 billion, reflecting slower-than-anticipated demand normalization for second-line Amvuttra and headwinds affecting the ATTR cardiomyopathy market. Fierce Pharma report on Amvuttra and guidance
• Negative Sentiment: The outlook cut raised concerns about the pace and durability of Amvuttra growth, Alnylam’s key commercial product. Multiple reports characterized the shares’ decline as a reaction to the weaker ATTR outlook and second-quarter revenue miss. MarketWatch report on Alnylam guidance
• Negative Sentiment: Several law firms announced securities-fraud investigations seeking investors who suffered losses. These announcements are often solicited investigations rather than evidence of wrongdoing, but they add reputational and legal overhang to the stock. Alnylam securities-fraud investigation announcement

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.